Literature DB >> 9615225

Structure and transcription regulation of the human insulin-like growth factor binding protein 4 gene (IGFBP4).

H Zazzi1, A Nikoshkov, K Hall, H Luthman.   

Abstract

Insulin-like growth factor binding protein 4 (IGFBP-4) is locally produced by normal human bone cells and acts as a potent inhibitor of IGF action in this tissue. PTH and a cAMP analog increase the expression of IGFBP4 mRNA in human osteoblast cells. We now show that the human IGFBP4 gene is contained within 15.3 kb with the transcription initiation site located 28 bp downstream of a TATA box sequence and 286 bp upstream of the translation initiation codon. The 3'-end of the mRNA was identified at position 14281, but no conserved poly(A) addition signal was found within 30 bp upstream of this site. Deletion mutagenesis located the core promoter activity downstream of position -289, and the transcription activity disappeared at -6. Stimulation with 0.5 mM dibutyryl-cAMP resulted in a twofold increase of promoter activity. Elements responsible for the cAMP response reside between positions -869 and -6.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9615225     DOI: 10.1006/geno.1998.5283

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  3 in total

Review 1.  The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge.

Authors:  Rajaraman Durai; Wenxuan Yang; Sharmila Gupta; Alexander M Seifalian; Marc C Winslet
Journal:  Int J Colorectal Dis       Date:  2005-01-14       Impact factor: 2.571

2.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.

Authors:  David J Degraff; Adam A Aguiar; Robert A Sikes
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

3.  Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray.

Authors:  J H Bull; G Ellison; A Patel; G Muir; M Walker; M Underwood; F Khan; L Paskins
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.